UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

BMC cancer, 2009-07, Vol.9 (1), p.263-263, Article 263

2009

Volltextzugriff (PDF)

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Journal for immunotherapy of cancer, 2016-03, Vol.4 (17), p.12-12, Article 12

2016

Volltextzugriff (PDF)

Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma

Cancer chemotherapy and pharmacology, 2013-12, Vol.72 (6), p.1305-1314

2013

Volltextzugriff (PDF)

Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e14546-e14546

2012

Volltextzugriff (PDF)

Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9008-9008a

2014

Volltextzugriff (PDF)

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma

Journal of clinical oncology, 2013-06, Vol.31 (18_suppl), p.LBA9008-LBA9008

2013

Volltextzugriff (PDF)

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy

Drug target insights, 2008-01, Vol.3 (1), p.55-66

2008

Volltextzugriff (PDF)

Long-term follow-up of DNA engineered bi-shRNA furin GMCSF plasmid/autologous tumor induced immune response in patients with advanced solid tumors (phase I trial)

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.110-110

2017

Volltextzugriff (PDF)

Chemoinducible gene therapy

Anti-cancer drugs, 2005-11, Vol.16 (10), p.1053-1058

2005

Volltextzugriff (PDF)

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy

Drug Target Insights, 2008, Vol.2008 (3), p.DTI.S649

2008

Volltextzugriff (PDF)

Clinical trial in progress: A phase 3 study of maintenance bi-shRNA-furin/GM-CSF-expressing autologous tumor cell vaccine in women with stage IIIb-IV high-grade epithelial ovarian cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS5604-TPS5604

2017

Volltextzugriff (PDF)

A bi-shRNA furin and GMCSF engineered autologous tumor cell immunotherapy vs. gemcitabine + docetaxel for Ewing sarcoma and with cryoablation in Ewing family tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS11079-TPS11079

2017

Volltextzugriff (PDF)

Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial

Cancer, 2001-08, Vol.92 (4), p.875-885

2001

Volltextzugriff (PDF)

Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774)

Clinical cancer research, 2004-10, Vol.10 (19), p.6522-6527

2004

Volltextzugriff (PDF)

Survival effect of bi-shRNA furin /GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to α-interferon-ELISPTOT response

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3077-3077

2014

Volltextzugriff (PDF)

Pilot trial of vigil immunotherapy in Ewing’s sarcoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.10522-10522

2015

Volltextzugriff (PDF)

Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.6082-6082

2014

Volltextzugriff (PDF)

A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2504-2504

2013

Volltextzugriff (PDF)

Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3621-3621

2013

Volltextzugriff (PDF)

A phase I trial of intratumoral administration of HF10 in patients with refractory superficial cancer: Immune correlates of virus injection

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3099-3099

2013

Volltextzugriff (PDF)

PX-866 and docetaxel in patients with advanced solid tumors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3024-3024

2012

Volltextzugriff (PDF)

A phase I study of oral darinaparsin in patients (pts) with advanced solid tumors (AST)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13040-e13040

2012

Volltextzugriff (PDF)

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.LBA9008-LBA9008

2013

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(62)

Sprache

Englisch
(62)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(22)
Oncology
(14)
Female
(10)
Male
(10)
Aged
(9)
Middle Aged
(9)
Neoplasms - Therapy
(8)
Pharmacology & Pharmacy
(8)
Cancer
(7)
Medicine, Research & Experimental
(7)
Neoplasms - Genetics
(7)
Research & Experimental Medicine
(7)
Adult
(6)
Genetic Therapy - Methods
(6)
Biotechnology & Applied Microbiology
(5)
Chemotherapy
(5)
Tumors
(5)
Adenoviridae - Genetics
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma

Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma

Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca)

Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy

Long-term follow-up of DNA engineered bi-shRNA furin GMCSF plasmid/autologous tumor induced immune response in patients with advanced solid tumors (phase I trial)

Chemoinducible gene therapy

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy

Clinical trial in progress: A phase 3 study of maintenance bi-shRNA-furin/GM-CSF-expressing autologous tumor cell vaccine in women with stage IIIb-IV high-grade epithelial ovarian cancer

A bi-shRNA furin and GMCSF engineered autologous tumor cell immunotherapy vs. gemcitabine + docetaxel for Ewing sarcoma and with cryoablation in Ewing family tumors

Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial

Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774)

Survival effect of bi-shRNA furin /GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to α-interferon-ELISPTOT response

Pilot trial of vigil immunotherapy in Ewing’s sarcoma

Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers

A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients

Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer

A phase I trial of intratumoral administration of HF10 in patients with refractory superficial cancer: Immune correlates of virus injection

PX-866 and docetaxel in patients with advanced solid tumors

A phase I study of oral darinaparsin in patients (pts) with advanced solid tumors (AST)

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma

Aktive Filter

Suchergebnisse filtern